EMCURE

What Emcure Pharmaceuticals promised, and what happened

Every commitment management made on a call, tracked from the quarter it was made — reaffirmed, revised, diluted or quietly dropped.

Guidance record · Q1 FY27

what the last two calls moved 17 tracked 0 delivered 7 missed 10 open
  • Revenue Growth went quiet said Q4 FY25 Promised: 13% to 14% in FY '26 Q1 FY27: Not addressed as the promise pertains to the completed FY26.
  • Net Debt on track said Q3 FY25 Promised: Net Cash by March 2026 Q1 FY27: Net debt increased to ₹1,103 cr. Management expects a temporary rise in Q2 due to M&A payouts, but reiterated the goal to be net cash by end of FY28.

The rest of the ledger

Above is what the last two calls moved. Pro opens all 17 tracked commitments for Emcure Pharmaceuticals — every quarter's revision, the source quote behind each one, and the topics management has stopped answering.

See what Pro opens